Omidenepag isopropyl ophthalmic solution for open-angle glaucoma and ocular hypertension: an update

References

• Weinreb RN, Friedman DS, Fechtner RD, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol. 2004;138(3):458–467.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–1911.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Early manifest glaucoma trial group. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268–1279.
   PubMed Web of Science ®Google Scholar
• Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295–1304.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Wolfs RCW, O’Colmain BJ, et al. Eye diseases prevalence research group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532–538.
   PubMedGoogle Scholar
• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090.
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Xalatan® (Latanoprost Ophthalmic Solution) 0.005%. Prescribing Information. New York City, NY: Pfizer, Inc.; 2014.
   Google Scholar
• Allergan, Inc. Lumigan® (Bimatoprost Ophthalmic Solution) 0.01%. Prescribing Information. Irvine, CA: Allergan, Inc.; 2017.
   Google Scholar
• Alcon Laboratories, Inc. Travatan Z® (Travoprost Ophthalmic Solution) 0.004%. Prescribing Information. Fort Worth, TX: Alcon Laboratories, Inc.; 2017.
   Google Scholar
• Akorn, Inc. Zioptan® (Tafluprost Ophthalmic Solution) 0.0015%. Prescribing Information. Lake Forest, IL: Akorn, Inc; 2014.
   Google Scholar
• Bausch & Lomb, Inc. Timoptic 0.25% and 5% (Timolol Maleate Ophthalmic Solution). Prescribing Information. Bridgewater, NJ: Bausch & Lomb, Inc.; 2016.
   Google Scholar
• Sonntag JR, Brindley GO, Shields MB. Effect of timolol therapy on outflow facility. Invest Ophthalmol Vis Sci. 1978;17(3):293–296.
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. Trusopt® (Dorzolamide Hydrochloride Ophthalmic Solution) 2%. Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; 2014.
   Google Scholar
• Alcon Laboratories, Inc. Azopt® (Brinzolamide Ophthalmic Suspension) 1%. Prescribing Information. Fort Worth, TX: Alcon Laboratories, Inc.; 2015.
   Google Scholar
• Allergan, Inc. Alphagan® P (Brimonidine Tartrate Ophthalmic Solution) 0.1% and 0.15%. Prescribing Information. Irvine, CA: Allergan, Inc; 2013.
   Google Scholar
• Aerie Pharmaceuticals, Inc. Rhopressa® (Netarsudil Ophthalmic Solution) 0.02%. Prescribing Information. Irvine, CA: Aerie Pharmaceuticals, Inc.; 2017.
   Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. K-115 Clinical Study Group. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731–736.
   PubMed Web of Science ®Google Scholar
• Somerset Therapeutics. Pilocarpine prescribing information. Somerset, NJ 2019.
   Google Scholar
• Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30–6.
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Dayno M, Robin AL. Systematic review of educational interventions to improve glaucoma medication adherence: an update in 2015. Expert Rev Ophthalmol. 2016;11(1):5–20.
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308–1316.
   PubMed Web of Science ®Google Scholar
• Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006;17(2):190–195.
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Niziol LM, Gillespie BW, et al. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020;127(4):477–483.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334.
   PubMed Web of Science ®Google Scholar
• Labbe A, Terry O, Brasnu E, et al. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012;31(9):994–999.
   PubMed Web of Science ®Google Scholar
• Ghosh S, O’Hare F, Lamoureux E, et al. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Exp Ophthalmol. 2012;40(7):675–681.
   PubMed Web of Science ®Google Scholar
• Valente C, Iester M, Corsi E, et al. Symptoms and signs of tear film dysfunction in glaucomatous patients. J Ocul Pharmacol Ther. 2011;27(3):281–285.
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013;23(3):296–302.
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1–9.
   PubMed Web of Science ®Google Scholar
• Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81(8):574–577.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Perren B, Iliev ME, et al. [Orbital fat atrophy in glaucoma patients treated with topical bimatoprost–can bimatoprost cause enophthalmos?]. Klin Monbl Augenheilkd. 2008;225(4):443–445.
   PubMed Web of Science ®Google Scholar
• Filippopoulos T, Paula JS, Torun N, et al. Periorbital changes associated with topical bimatoprost. Ophthalmic Plast Reconstr Surg. 2008;24(4):302–307.
   PubMed Web of Science ®Google Scholar
• Miki T, Naito T, Fujiwara M, et al. Effects of presurgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS One. 2017;12(7):e0181550.
   PubMed Web of Science ®Google Scholar
• Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103(2):147–166.
   PubMed Web of Science ®Google Scholar
• Crowston JG, Lindsey JD, Aihara M, et al. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest Ophthalmol Vis Sci. 2004;45(10):3555–3559.
   PubMed Web of Science ®Google Scholar
• Oh DJ, Martin JL, Williams AJ, et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest Ophthalmol Vis Sci. 2006;47(3):953–963.
   PubMed Web of Science ®Google Scholar
• Richter M, Krauss AHP, Woodward DF, et al. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44(10):4419–4426.
   PubMed Web of Science ®Google Scholar
• Yen JH, Kocieda VP, Jing H, et al. E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation. J Biol Chem. 2011;286(45):38913–38923.
   PubMed Web of Science ®Google Scholar
• Saeki T, Ota T, Aihara M, et al. Effects of prostanoid EP agonists on mouse intraocular pressure. Invest Ophthalmol Vis Sci. 2009;50(5):2201–2208.
   PubMed Web of Science ®Google Scholar
• Nilsson SFE, Drecoll E, Lütjen-Drecoll E, et al., The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 2006;47(9): 4042–4049.
   PubMed Web of Science ®Google Scholar
• Esaki Y, Katsuta O, Kamio H, et al. The antiglaucoma agent and EP2 receptor agonist omidenepag does not affect eyelash growth in mice. J Ocul Pharmacol Ther. 2020;36(7):529–533.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Taniguchi T, Inazumi T, et al. Effects of the selective EP2 receptor agonist omidenepag on adipocyte differentiation in 3T3-L1 cells. J Ocul Pharmacol Ther. 2020;36(3):162–169.
   PubMed Web of Science ®Google Scholar
• Fuwa M, Toris CB, Fan S, et al., Effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys. J Ocul Pharmacol Ther. 2018;34(7): 531–537.
   PubMed Web of Science ®Google Scholar
• Kirihara T, Taniguchi T, Yamamura K, et al., Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent. Invest Ophthalmol Vis Sci. 2018;59(1): 145–153.
   PubMed Web of Science ®Google Scholar
• Nakakura S, Terao E, Fujisawa Y, et al. Changes in prostaglandin-associated periorbital syndrome after switch from cnventional prostaglandin F2α treatment to omidenepag isopropyl in 11 consecutive patients. J Glaucoma. 2020;29(4):326–328.
   PubMed Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata H, et al. Pharmacokinetics, safety, and intraocular pressure-lowering profile of omidenepag isopropyl, a selective, nonprostaglandin, prostanoid EP2 receptor agonist, in healthy Japanese and Caucasian volunteers (phase I study). J Ocul Pharmacol Ther. 2019;35(10):542–550.
   PubMed Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata H, et al., Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2019;28(5): 375–385.
   PubMed Web of Science ®Google Scholar
• Duggan S. Omidenepag isopropyl ophthalmic solution 0.002%: first global approval. Drugs. 2018;78(18):1925–1929.
   PubMed Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata A, et al. Six-month efficacy and safety outcomes of a novel selective EP2 agonist omidenepag isopropyl: the Renge study (phase 3). Invest Ophthalmol Vis Sci. 2018;59(9):1229.
   PubMed Web of Science ®Google Scholar
• Santen Pharmaceutical Co., Inc. EYBELIS ophthalmic solution 0.002%. Prescribing information [Japanese]. Osaka, Japan: Santen Pharmaceutical Co.; 2018. Available from: http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/300237_13197C0Q1028_1_02
   Google Scholar
• Lima MC, Jr PA, Salim S, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000;9(4):317–321.
   PubMed Web of Science ®Google Scholar
• Wand M, Gaudio AR, Shields MB. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes. J Cataract Refract Surg. 2001;27(9):1397–1401.
   PubMed Web of Science ®Google Scholar
• Wendel C, Zakrzewski H, Carleton B, et al. Association of postoperative topical prostaglandin analog or beta-blocker use and incidence of pseudophakic cystoid macular edema. J Glaucoma. 2018;27(5):402–406.
   PubMed Web of Science ®Google Scholar
• Olander K, Sato MA, Abrams MA, et al. A randomized phase 2 trial assessing the safety and efficacy of omidenepag isopropyl 0.002% once and twice daily in subjects with primary open-angle glaucoma or ocular hypertension (Spectrum 6). Invest Ophthalmol Vis Sci. 2020;61(7):4258.
   Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata H, et al. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the Phase 3 AYAME study. Am J Ophthalmol. 2020;220:53–63.
   PubMed Web of Science ®Google Scholar
• Aihara M, Ropo A, Lu F, et al., Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. Jpn J Ophthalmol. 2020;64(4): 398–406.
   PubMed Web of Science ®Google Scholar
• Oogi S, Nakakura S, Terao E, et al. One-year follow-up study of changes in prostaglandin-associated periorbital syndrome after switch from conventional prostaglandin F2α to omidenepag isopropyl. Cureus. 2020;12(8):e10064.
   PubMed Web of Science ®Google Scholar
• Inoue K, Inoue J, Kunimatsu-Sanuki S, et al. Short-term efficacy and safety of omidenepag isopropyl in patients with normal-tension glaucoma. Clin Ophthalmol. 2020;14:2943–2949.
   PubMed Web of Science ®Google Scholar
• Nakakura S, Kanamori A, Fukuma Y, et al. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study. BMJ Open. 2021;11(1):e040301.
   PubMed Web of Science ®Google Scholar
• Skorin L, Dailey KH. Clicking eyelids: a new finding of prostaglandin-associated periorbitopathy. Optom Vis Sci. 2016;93(7):779–781.
   PubMed Web of Science ®Google Scholar
• Abedi F, Chappell A, Craig JE. Audible clicking on blinking: an adverse effect of topical prostaglandin analogue medication. Clin Exp Ophthalmol. 2017;56(3):304–306.
   Web of Science ®Google Scholar